Flight attendantS at American Airlines (AA) are pissed. The mean and evil airline announced that it will no longer cover GLP-1 medications for weight management for crew members.
American Airlines Slashes Benefits for Flight Attendants Weight-Loss Drug
Flight Attendant Union rebels against benefit cuts at American Airlines
By Karan Bhatta October 21, 2025
TEXAS – The flight attendant workforce at American Airlines (AA) is expressing sharp dissatisfaction after the airline announced that it will no longer cover GLP-1 medications for weight management for crew members, only for those with Type 2 diabetes.
From January 1, 2026 the policy will apply to all U.S.-based flying crew. The move affects popular weight-loss drugs such as Ozempic and Mounjaro when used outside of a diabetes diagnosis. The airline remains committed to covering GLP-1 drugs for diabetes treatment.
Coverage Change Details
American Airlines has informed crew members that starting in 2026 the company’s health plan will exclude GLP-1 medications for weight loss unless an individual has a documented Type 2 diabetes diagnosis.
Medications like Ozempic and Mounjaro will remain covered only under that indication. This aligns with a broader industry trend where employers cite soaring costs of these drugs when used for weight management.
The carrier’s union representing flight attendants, the Association of Professional Flight Attendants (APFA), labelled the decision “unilateral” and argued it undermines the value of their health coverage, reported Paddle Your Own Kanoo.
The union said the change removes a critical option for crew members who rely on these medications for preventive or chronic health purposes
Industry Cost Pressures
The cost burden of GLP-1 medications is substantial and growing. Reports indicate annual costs for treating obesity with these drugs can run into the thousands per patient, and employers face difficult decisions balancing coverage and affordability.
Health insurers and large employers have already begun reducing or eliminating coverage for GLP-1 treatments when used for weight loss rather than diabetes.
For instance, one major commercial insurer announced the exclusion of weight-loss GLP-1 coverage starting January 1, 2026. American Airlines’ move fits within this wider trend even as the union challenges the logic and argues crew health is being unduly compromised.
Union Reaction and Next Steps
The APFA has demanded that American Airlines engage in negotiations or provide alternative benefit design options, such as copay caps, generics or tiered coverage.
The union emphasises the change reduces the effective value of health coverage for members and may impact their broader wellbeing.
The airline has thus far declined to incorporate those alternatives and maintains that its health-benefit strategy must address cost sustainability.
Members have been encouraged to seek individual assistance options, but systemic change remains the union’s objective. The dispute may continue into contract negotiations or mediation.
Bottom Line
American Airlines’ decision to restrict GLP-1 medication coverage for weight management among flight attendants reflects broader cost pressures in employer-sponsored health plans.
Crew members have reacted strongly through their union, citing diminished coverage and fewer health treatment options.
While the airline claims the move is fiscally responsible, the union and many affected employees see it as a step backward for employee wellbeing.
Stay tuned with us. Further, follow us on social media for the latest updates.
SOURCE: American Airlines Slashes Benefits for Flight Attendants Weight-Loss Drug – Aviation A2Z
